Skip to main content
. 2018 Sep 20;19(10):2846. doi: 10.3390/ijms19102846

Figure 1.

Figure 1

CMS-2 antimetastatic activity in murine melanoma B16-F10. (A) The number of metastatic points in lungs of C57/BL6 mice (n = 50) after 15 days of subcutaneous treatment with saline (control), carboplatin (positive control), CMS-1 or CMS-2. *** p < 0.001 and **** p < 0.0001, analysis of variance, Mann–Whitney post-test. (B) Representative images of lungs from control or treated mice.